Every day, our community of researchers, investigators, scientists, sarcoma centers, and biotech and pharmaceutical companies are working together in the development and support of clinical trials (studies). A list of SARC trials is provided here with a brief description and patient accrual status. Additionally, the National Institutes of Health provides an online registry and results database of clinical studies conducted around the world.

patient seated waiting to receive treatment

Active SARC Trials

SARC041

Phase 3 Randomized Double-Blind Study of Abemaciclib Versus Placebo in Patients With Advanced Dedifferentiated Liposarcoma

TYPE OF SARCOMA: Advanced Dedifferentiated Liposarcoma
DRUG: Abemaciclib

ACCRUAL STATUS: Now recruiting for patients

(more…)

SARC038

Phase 2 Study of Regorafenib and Nivolumab in Osteosarcoma

TYPE OF SARCOMA: Osteosarcoma
DRUG: Regorafenib, Nivolumab

(more…)

SARC037

A Phase I/II Study to Evaluate the Safety of Trabectedin Administered as a 1-Hour infusion in Ewing Sarcoma Patients in Combination with Low Dose Irinotecan and 3’-Deoxy-3’-18F Fluorothymidine (18F-FLT) Imaging

TYPE OF SARCOMA: Ewing Sarcoma
DRUG: Trabectedin and Irinotecan

ACCRUAL STATUS: Not Recruiting

(more…)

SARC033

A Non-Randomized, Open-Label, Phase 2 Study of Trametinib in Patients With Unresectable or Metastatic Epithelioid Hemangioendothelioma

TYPE OF SARCOMA: Epithelioid Hemangioendothelioma
DRUG: Trametinib

(more…)

SARC032-SU2C

A Phase II Randomized Controlled Trial of Neoadjuvant Pembrolizumab With Radiotherapy and Adjuvant Pembrolizumab in Patients With High-Risk, Localized Soft Tissue Sarcoma of the Extremity

TYPE OF SARCOMA: Soft Tissue Sarcoma of the Extremity
DRUG: Pembrolizumab

ACCRUAL STATUS: Not recruiting

(more…)

SARC031

A Phase 2 Trial of the MEK Inhibitor Selumetinib (AZD6244 Hydrogen Sulfate) in Combination with the mTOR Inhibitor Sirolimus for Patients with Unresectable or Metastatic Malignant Peripheral Nerve Sheath Tumors

TYPE OF SARCOMA: Unresectable or Metastatic NF1 Associated or Sporadic Malignant Peripheral Nerve Sheath Tumors (MPNST)
DRUG: Selumetinib in Combination with Sirolimus

(more…)
Back to top